Skip to main content

Table 5 Univariate analysis of prognostic survival factors for 2nd and 3rd line therapy

From: Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients

  Survival after 2nd line therapy Survival after 3rd line therapy
  HR 95%-CI p-value HR 95%-CI p-value
Sex    0.120    0.415
Female 0.77 0.56-1.07   0.83 0.53-1.30  
Male 1    1   
Age    0.015    0.007
< 70 years 1    1   
≥ 70 years 0.63 0.43-0.91   0.48 0.28-0.82  
Smoking status*    0.032    0.012
Never smoker 0.56 0.34-0.93   0.43 0.21-0.86  
Former smoker 0.69 0.48-0.99   0.53 0.32-0.87  
Current smoker 1    1   
Histology    0.037    0.597
Adenocarcinoma 0.59 0.40-0.88   0.89 0.46-1.7  
Squamous cell carcinoma 0.64 0.38-1.09   1.19 0.53-2.63  
Large cellundifferentiated carcinoma 1    1   
Response to previous therapy line    0.001    < 0.001
Disease control 0.58 0.41-0.81   0.44 0.29-0.69  
Progress 1    1   
Response to both previous therapy lines    NA    < 0.001
Disease control in both previous lines   0.26 0.13-0.51  
Disease control in any previous line   0.53 0.28-0.99  
Progress in both previous lines   1   
  1. HR, hazard ratio; CI, confidence interval. *Patients with known smoking status.
  2. “─” indicates that data could not be calculated.